Bacille Calmette-Guérin Nmibc gemcitabine intravesical therapy meta-analysis non-muscle invasive bladder cancer

Administration Intravesical Antineoplastic Agents/*administration & dosage Humans Infusions Intra-Arterial Meta-Analysis as Topic Systematic Reviews as Topic Urinary Bladder Neoplasms/*drug therapy

Adjuvants Immunologic/*therapeutic use Administration Intravesical BCG Vaccine/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Cystoscopy Female Humans Male Multivariate Analysis Muscle Smooth/*pathology Neoplasm Invasiveness Neoplasm Recurrence Local/*epidemiology Proportional Hazards Models Sex Factors Survival Rate Urinary Bladder Neoplasms/pathology/*therapy *Urologic Surgical Procedures Bladder cancer Gender differences Local recurrence Meta-analysis Transurethral resection of bladder tumor

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Disease-Free Survival Humans Saline Solution/*administration & dosage/adverse effects *Therapeutic Irrigation/adverse effects Urinary Bladder Neoplasms/*surgery Water/*administration & dosage/adverse effects

Administration Intravesical Antineoplastic Agents/*pharmacology Humans Maintenance Chemotherapy/*methods Neoplasm Invasiveness Neoplasm Recurrence Local/*prevention & control Prognosis Randomized Controlled Trials as Topic Treatment Outcome *Urinary Bladder Neoplasms/drug therapy/pathology Bladder cancer Chemotherapy Intravesical Maintenance

Administration Intravesical Aged Aged 80 and over BCG Vaccine/*therapeutic use Biopsy Needle Disease-Free Survival Female Humans Immunohistochemistry Immunotherapy/*methods In Situ Hybridization Fluorescence Male Middle Aged Neoplasm Recurrence Local/mortality/*pathology Predictive Value of Tests Prognosis Risk Assessment Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Bcg Bladder cancer Immunotherapy Personalized therapy Response prediction

Epirubicin/*therapeutic use Female Humans Immunotherapy/*methods Male Mitomycin/*therapeutic use *Mycobacterium bovis Urinary Bladder Neoplasms/immunology/pathology/*therapy Bacillus Calmette–Guérin Consistency Epirubicin Gemcitabine Heterogeneity Interferon-Alpha Intravesical instillation therapies Mitomycin C Pairwise/network meta-analysis Tumor progression Tumor recurrence

Adjuvants Immunologic/*administration & dosage Administration Intravesical Antineoplastic Agents/therapeutic use BCG Vaccine/*administration & dosage Humans Instillation Drug Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/pathology/*therapy Bacillus Calmette-Guerin Maintenance therapy Non-muscle-invasive bladder cancer Progression Recurrence

Adjuvants Immunologic/*administration & dosage/adverse effects Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects BCG Vaccine Carcinoma in Situ/mortality/pathology/*therapy Combined Modality Therapy/adverse effects/methods Disease Progression Drug Administration Schedule Humans Interferon-alpha/*administration & dosage/adverse effects Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/mortality/pathology/*therapy Withholding Treatment/statistics & numerical data

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Asymptomatic Diseases BCG Vaccine/*administration & dosage/adverse effects Bacteriuria/*complications/diagnosis Humans Immunotherapy/adverse effects/*methods Neoplasm Invasiveness Risk Assessment Treatment Outcome Urinary Bladder Neoplasms/complications/*drug therapy/immunology/pathology Bacillus Calmette-Guerin Bacteriuria Bladder cancer Intravesical instillation

Administration Intravesical Antibiotics Antineoplastic/*administration & dosage BCG Vaccine/administration & dosage Carcinoma in Situ/*drug therapy/mortality/pathology Carcinoma Transitional Cell/*drug therapy/mortality/pathology Disease Progression Electrochemotherapy/adverse effects/*methods Humans Mitomycin/*administration & dosage Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

Administration Intravesical BCG Vaccine/therapeutic use Disease Progression Female Humans *Ki-67 Antigen Male *Neoplasm Invasiveness Prognosis Prospective Studies *Urinary Bladder Neoplasms/diagnosis/drug therapy/pathology Ki67 meta-analysis non-muscular-invasive bladder cancer

Administration Intravesical BCG Vaccine/administration & dosage/*therapeutic use Chemotherapy Adjuvant Dose-Response Relationship Drug Drug Administration Schedule Humans Neoplasm Recurrence Local Prospective Studies Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/mortality/surgery

Adjuvants Immunologic/administration & dosage Administration Intravesical Antineoplastic Agents/therapeutic use BCG Vaccine/*administration & dosage Bayes Theorem Disease Progression Humans Immunotherapy/*methods Incidence Neoplasm Recurrence Local/drug therapy Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy Intravesical bacillus Calmette–Guerin efficacy maintenance non-muscle-invasive bladder cancer side effects

Administration Intravesical Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects BCG Vaccine/administration & dosage Bayes Theorem Deoxycytidine/administration & dosage/analogs & derivatives Disease Progression Epirubicin/administration & dosage Female Humans Isoniazid/administration & dosage Male Middle Aged Mitomycin/administration & dosage Neoplasm Invasiveness Neoplasm Recurrence Local Odds Ratio Randomized Controlled Trials as Topic Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/mortality/pathology Gemcitabine efficacy and safety intravesical therapy non-muscle invasive bladder cancer tumor progression tumor recurrence

Administration Intravesical Antineoplastic Combined Chemotherapy Protocols/*administration & dosage Carcinoma Transitional Cell/mortality/*pathology/*therapy Disease Progression Doxorubicin/administration & dosage/analogs & derivatives Epirubicin/administration & dosage Humans Mitomycin/administration & dosage Neoplasm Recurrence Local/*prevention & control Neoplasm Staging Randomized Controlled Trials as Topic Risk Factors Survival Rate Thiotepa/administration & dosage Time Factors Urinary Bladder Neoplasms/mortality/*pathology/*therapy Chemotherapy Meta-analysis Non–muscle-invasive bladder cancer Single instillation Systematic review

Administration Intravesical Antineoplastic Agents/administration & dosage/*therapeutic use BCG Vaccine/administration & dosage/*therapeutic use Humans Treatment Outcome Urinary Bladder Neoplasms/*drug therapy

Administration Intravesical Antineoplastic Agents/*administration & dosage Antineoplastic Combined Chemotherapy Protocols/administration & dosage Carcinoma Transitional Cell/*drug therapy/mortality Cyclophosphamide/administration & dosage Doxorubicin/administration & dosage/analogs & derivatives Epirubicin/administration & dosage Humans Melphalan/administration & dosage Network Meta-Analysis Semustine/administration & dosage Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/mortality chemotherapy drug therapy single instillation systematic review urinary bladder neoplasm